Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Capital Expenditures (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Capital Expenditures for 14 consecutive years, with -$4.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 3939.52% year-over-year to -$4.8 million, compared with a TTM value of $4.9 million through Sep 2025, down 18.6%, and an annual FY2024 reading of $140000.0, down 97.72% over the prior year.
  • Capital Expenditures was -$4.8 million for Q4 2025 at Fate Therapeutics, down from $2.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $30.9 million in Q3 2021 and bottomed at -$28.0 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $585950.0, with a median of $123500.0 recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 8442.86% in 2025, while the deepest fall reached 3939.52% in 2025.
  • Year by year, Capital Expenditures stood at -$28.0 million in 2021, then skyrocketed by 96.66% to -$933000.0 in 2022, then skyrocketed by 741.48% to $6.0 million in 2023, then crashed by 97.93% to $124000.0 in 2024, then crashed by 3939.52% to -$4.8 million in 2025.
  • Business Quant data shows Capital Expenditures for FATE at -$4.8 million in Q4 2025, $2.2 million in Q3 2025, and $1.4 million in Q2 2025.